MIST

Milestone Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website milestonepharma.com
Employees(FY) 39
ISIN CA59935V1076

Performance

+3.03%

1W

-5.56%

1M

+10.39%

3M

-42.86%

6M

+1.8%

YTD

-56.63%

1Y

Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Advanced Technical Analysis

Technical Analysis of MIST 2024-05-03

Overview:

In analyzing the technical indicators for MIST stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key aspects, we aim to offer valuable insights and recommendations for potential investor...

See more ...

Recent News & Updates

2024-05-01 20:00
Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024(Globenewswire)
2024-04-16 20:00
Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium(Globenewswire)
2024-04-07 23:36
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting(Globenewswire)
2024-04-02 20:00
Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference(Globenewswire)
2024-03-31 20:00
Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences(Globenewswire)
2024-03-27 19:00
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia(Globenewswire)
2024-03-21 01:53
MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023(Investorplace)
2024-03-20 19:14
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update(Globenewswire)
2024-02-29 03:01
Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference(Globenewswire)
2024-02-28 18:00
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants(Globenewswire)
2024-02-28 03:37
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants(Globenewswire)
2024-02-25 18:00
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT(Globenewswire)
2024-01-18 00:23
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm(Globenewswire)
2024-01-15 20:35
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround(Zacks)
2023-12-26 22:11
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil(Yahoo Finance)
2023-12-25 21:55
Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm(Globenewswire)
2023-12-25 18:00
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT(Globenewswire)
2023-11-20 18:00
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference(Prnewswire)
2023-11-12 18:02
Milestone Pharmaceuticals: Q3 Earnings Snapshot(Yahoo Finance)
2023-11-12 17:57
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates(Prnewswire)
2023-11-10 21:00
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023(Prnewswire)
2023-11-06 18:00
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR(Prnewswire)
2023-10-23 19:00
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil(Prnewswire)
2023-10-05 19:00
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)(Prnewswire)
2023-09-26 19:00
Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023(Prnewswire)
2023-09-04 19:00
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-09 19:56
Milestone Pharmaceuticals: Q2 Earnings Snapshot(Yahoo Finance)
2023-08-09 19:35
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update(Yahoo Finance)
2023-08-07 21:55
2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More)(Yahoo Finance)
2023-06-19 19:00
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet(Yahoo Finance)

Page 1 of 4

previousnext